2invest AG

Latest Results (14.06.2026):

2invest AG — results for Q4 2020 (full-year 2020): the company reported a strong turnaround in FY2020 driven by the sale of its proteomics and immunology businesses to Abcam. For the year ended 31 December 2020 2invest AG recorded a net profit of EUR 55.0 million, materially higher cash and marketable securities (total freely available cash & securities ~EUR 66.3m) and a transformed business model toward an investment company following a December 2020 spin-off of operating units.

Net result

FY2020 net profit: TEUR 55,033 (≈ EUR 55.0m), vs. a net loss of TEUR -32,832 in 2019. The result is largely driven by a net gain of TEUR 68,354 (≈ EUR 68.4m) reported as other operating income from the Abcam transaction.

Revenue and operating items

Reported revenue remained negligible (TEUR 69) — largely management recharges. Other operating expenses rose to TEUR 12,013, largely due to restructuring expenses of TEUR 9,700 related to capital injections and repayments in the subsidiaries that were spun off.

Cash, securities and escrow

Freely available cash and bank balances: EUR 47.2m; listed securities: EUR 19.1m — total cash + securities ≈ EUR 66.3m as at 31‑12‑2020. In addition, escrow cash claims related to the Abcam deal of EUR 14.4m (to be released January 2022) provide extra contingent liquidity.

Balance sheet and equity

Total assets at 31‑12‑2020: TEUR 85,565 (≈ EUR 85.6m). Equity rose to TEUR 84,501 (≈ EUR 84.5m), reflecting the FY2020 profit and capital movements (including share conversions and a share buyback programme during 2020).

Major transaction & strategic change

Sale to Abcam (effective 1‑Jan‑2020) produced the large cash inflow and gain. In Dec‑2020 2invest AG completed a spin-off of the remaining genomics/DNA units into 4basebio UK Societas (formerly 4basebio SE). The company has repositioned itself as an investment company focused on deploying the Abcam proceeds into listed securities and other investments.

Cash flow

FY2020 cash flows: operating activities used TEUR 7,827 (≈ -EUR 7.8m); investing activities provided TEUR 63,799 (≈ +EUR 63.8m) primarily from the Abcam proceeds; financing activities were TEUR -8,879 (≈ -EUR 8.9m), impacted by share buybacks and other repayments. Cash on hand rose from EUR 0.1m to EUR 47.2m.

Investments shown on the balance sheet

After the spin-off, 2invest AG reports an investment in 4basebio UK Societas at book value ≈ EUR 4.5m. The spun-off entity’s shares were admitted to AIM on 17‑Feb‑2021; post-spin-off shareholders hold ~70% of that company while 2invest AG retained ~30%.

Audit and governance

Ernst & Young GmbH audited the FY2020 financial statements and issued an unqualified (clean) audit opinion. The Supervisory Board reviewed and approved the annual financial statements on 29‑Apr‑2021.

Risks and outlook

Management states it expects continued macroeconomic uncertainty (COVID‑19) but believes liquidity is sufficient to manage near‑term risks. Key risks going forward include market/price risk on invested securities, currency exposure (non‑EUR holdings), and reliance on a single Management Board member for operations.